natgillin/translations-raw huggingface dataset:
astenopi, konjunktivalt ødem, fotofobi, øget tåreflåd, hyperpigmentering af iris, sløret syn, øjenlågskløe, øjenlågsødem
asthenopia, conjunctival oedema, photophobia, lacrimation increased, iris hyperpigmentation, blurred vision, eyelid pruritus, eyelid oedema
astenopi, sløret syn, konjunktivitis, konjunktivalt ødem, hyperpigmentering af iris, tab af øjenvipper, øjenlågsødem
asthenopia, blurred vision, conjunctival disorder, conjunctival oedema, iris hyperpigmentation, madarosis, eyelid oedema
Astheni Brystsmerter Kuldegysninger Pyreksi Utilpashed Smerter Perifere ødemer
Asthenia Chest Pain Chills Pyrexia Malaise Pain Oedema peripheral
asthma eller anden lungesygdom
asthma or any other disease of the lungs
Asthma,
Rhinorrhoea
astma
asthma
Astma Dyspnø Gaben
Asthma
astma eller andre vejrtrækningsproblemer
asthma or other breathing problems
Astma eller sygehistorie med bronkospasme
Asthma or history of bronchospasm
Astma er i øjeblikket en anført ADR i produktinformationen om timolol.
Asthma is currently a listed ADR in the timolol Product Information.
astma og lignende symptomer, pleural effusion og symptomer, kongestion og inflammation i luftvejene, hoste
asthma and related symptoms, pleural effusion and symptoms, respiratory tract congestion and inflammation, cough
Astma, allergisk rhinitis
Asthma, rhinitis allergic
astma, bronchioliti s obliterans,
asthma, bronchiolitis obliterans, lung disorder, hypoxia
astma, dyspnø
asthma, dyspnoea.
astma, dyspnø, dysfoni, nasal kongestion
asthma, dyspnoea, dysphonia, nasal congestion
astma, forpustethed;
asthma, shortness of breath;
astma, forværring af astma, forværring af KOL og dyspnø
asthma, asthma exacerbation, COPD exacerbation and dyspnoea
astma, kroppens organer får for lidt ilt opsvulmet mave.
asthma, too little oxygen reaching the body organs swelling of the stomach.
Astma, lungekongestion, sinusitis, nysen, hiven efter vejret
Asthma, Pulmonary congestion, Sinus disorder, Sneezing, Wheezing
Astma, åndenød, hvæsende vejrtrækning
Asthma, shortness of breath, wheezing
Astma- eksacerbatio n
Asthma exacerbation
Astma- eksacerbation
Asthma exacerbation
astma- eksacerbation†
Asthma exacerbation
astma;
asthma
Astmaeksacerbationer blev kun evalueret i eksacerbationsstudierne (studie I og II: reslizumab 3 mg/kg [n = 14] og placebo [n = 11]).
Asthma exacerbations were evaluated only in the exacerbation studies (Studies I and II: reslizumab 3 mg/kg [n=14] and placebo [n=11]).
astmalignende symptomer
Asthma-like symptoms
Astmapatienter skal behandles med den styrke af Relvar Ellipta, der indeholder den dosis fluticasonfuroat (FF), der passer til patientens sværhedsgrad af sygdommen.
Patients with asthma should be given the strength of Relvar Ellipta containing the appropriate fluticasone furoate (FF) dosage for the severity of their disease.
Astmapatienter skal behandles med den styrke af Revinty Ellipta, der indeholder den dosis fluticasonfuroat (FF), der passer til patientens sværhedsgrad af sygdommen.
Patients with asthma should be given the strength of Revinty Ellipta containing the appropriate fluticasone furoate (FF) dosage for the severity of their disease.
Astmarelaterede dødsfald
Asthma-related death
Astmavarighed, gennemsnit i år
Asthma duration, mean in years
Astmoor Industrial Estate Runcorn WA7 1NU Storbritannien
Astmoor Industrial Estate Runcorn WA7 1NU United Kingdom
ASTRAL-1 var et randomiseret, dobbeltblindt, placebokontrolleret studie, der evaluerede 12 ugers behandling med Epclusa versus med 12 uger med placebo hos patienter med genotype 1-, 2-, 4-, 5- eller 6-HCV-infektion.
ASTRAL-1 was a randomised, double-blind, placebo-controlled study that evaluated 12 weeks of treatment with Epclusa compared with 12 weeks of placebo in patients with genotype 1, 2, 4, 5, or 6 HCV infection.
ASTRAL-2 var et randomiseret åbent studie, der evaluerede 12 ugers behandling med Epclusa versus 12 ugers behandling med SOF+RBV hos patienter med genotype 2-HCV-infektion.
ASTRAL-2 was a randomised, open-label study that evaluated 12 weeks of treatment with Epclusa compared with 12 weeks of treatment with SOF+RBV in patients with genotype 2 HCV infection.
ASTRAL-3 var et randomiseret åbent studie, der evaluerede 12 ugers behandling med Epclusa versus 24 ugers behandling med SOF+RBV hos patienter med genotype 3-HCV-infektion.
ASTRAL-3 was a randomised, open-label study that evaluated 12 weeks of treatment with Epclusa compared with 24 weeks of treatment with SOF+RBV in patients with genotype 3 HCV infection.
ASTRAL-4 var et randomiseret åbent studie med patienter med genotype 1-, 2-, 3-, 4-, 5- eller 6- HCV-infektion og CPT-klasse B-cirrose.
ASTRAL-4 was a randomised, open-label study in patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and CPT Class B cirrhosis.
AstraZeneca AB, o.z.
Slovenská republika AstraZeneca AB, o.z.
AstraZeneca Pharmaceuticals (Ireland) Ltd Tel: + 353 1609 7100
AstraZeneca Pharmaceuticals (Ireland) Ltd Tel: +353 1609 7100
AstraZeneca S.p.A. Tel: + 39 02 9801 1
AstraZeneca S.p.A.
AstraZeneca S.p.A. Tel: + 39 02 9801 1
AstraZeneca S.p.A. Tel: +39 02 9801 1
AstraZeneca UK Limited, Macclesfield, Cheshire, SK10 2NA, Storbritannien
AstraZeneca UK Limited, Macclesfield, Cheshire, SK10 2NA, United Kingdom
AstraZeneca UK Ltd.‌‌
AstraZeneca UK Ltd.
Asympto- matisk
Asymptomatic
asymptomatisk
asymptomatic
asymptomatisk hyperlaktatæmi (ophobning af syre i blodet)
asymptomatic hyperlactatemia (build up of acid in your blood)
Asymptomatisk laboratorie-positiv Cytomegalovirus (CMV) viræmi bør ikke nødvendigvis betragtes som en alvorlig infektion, der kræver seponering af behandlingen..
Asymptomatic laboratory positive Cytomegalovirus (CMV) viraemia should not necessarily be considered a serious infection requiring interruption of therapy.
Asymptomatisk og
Asymptomatic and
Asymptomatisk stigning i kreatinin i blodprøver
Asymptomatic laboratory elevations in blood creatinine
Asymptomatisk, let forhøjelse af bilirubin i serum er observeret hos CAPS-patienter, der blev behandlet med Ilaris, uden samtidig forhøjelse af niveauet af transaminaser.
Asymptomatic and mild elevations of serum bilirubin have been observed in CAPS patients treated with Ilaris without concomitant elevations of transaminases.
Asymptomatiske grad 3-stigninger i aminotransferaser (ALAT/ASAT > 5x ULN) og bilirubin (total- bilirubin > 3x ULN) er rapporteret i et fase I-studie, hvor ipilimumab (3 mg/kg) og vemurafenib (960 mg to gange dagligt eller 720 mg to gange dagligt) blev administreret samtidigt.
In a Phase I trial, asymptomatic grade 3 increases in transaminases (ALT/AST >5 x ULN) and bilirubin (total bilirubin >3x ULN) were reported with concurrent administration of ipilimumab (3 mg/kg) and vemurafenib (960 mg BID or 720 mg BID).
Asymptomatiske tilfælde af bradykardi (hjertefrekvens under 60 bpm) er observeret hos 10 ud af 525 (1,9 %) patienter, der blev behandlet med ceritinib i kliniske studier.
Asymptomatic cases of bradycardia (heart rate less than 60 bpm) have been observed in 10 out of 525 (1.9%) patients treated with ceritinib in clinical studies.
At absorptionen af piperaquin forøges under tilstedeværende af fødevarer; for at reducere denne risiko for QTc-forlængelse skal patienterne derfor rådes til at tage tabletterne sammen med vand, uden føde, højst 3 timer efter den sidste indtagelse af fødevarer.
That piperaquine absorption is increased in the presence of food, therefore to reduce this risk of QTc interval prolongation, the patients should be advised to take the tablets with water, without food, no less than three hours after the last food intake.
at administration sammen med tenofovir, boceprevir, carbamazepin, phenytoin, phenobarbital, protonpumpehæmmere og buprenorphin frarådes. at administration sammen med famotidin frarådes, men om nødvendigt kan atazanavir uden ritonavir administreres enten 2 timer efter famotidin eller 12 timer før.
that co-administration is not recommended with tenofovir, boceprevir, carbamazepine, phenytoin, phenobarbital, proton pump inhibitors, and buprenorphine. that co-administration with famotidine is not recommended but if required, atazanavir without ritonavir should be administered either 2 hours after famotidine or 12 hours before.
At advare patienter mod håndkøbsmedicin, specielt perikon
To warn patients about OTC medicines in particular St John’s Wort
At alle patienter skal forsynes med et patientkort og rådgives om:
That all patients should be provided with a Patient alert card and be counselled about:
At alle patienter skal have patientinformationsmaterialet stillet til rådighed og skal have rådgivning om:
That all patients should be provided with the educational material and be counselled about:
At alle patienter skal have udleveret et patientinformationskort og rådgives om tegn eller symptomer på blødning og hvornår man skal søge hjælp hos sundhedspersonalet
That all patients should be provided with a Patient alert card and be counselled about signs or symptoms of bleeding and when to seek attention from a health care provider
At alle patienter skal have udleveret et patientoplysningskort og informeres om:
That all patients should be provided with a Patient alert card and be counselled about:
At alle patienter skal have vejledning i:
That all patients should be counselled about:
At antibiotisk følsomhedsbestemmelse minimerer risikoen for fejl i behandlingen ved at identificere de stammer, som potentielt kan være resistente for daptomycin.
That susceptibility testing minimises the risk of treatment failure by identifying strains with potential resistance to daptomycin.
at behandle sekundær hyperparathyreoidisme hos patienter med nyresygdom, der er i dialyse,
to treat secondary hyperparathyroidism in patients with kidney disease on dialysis.
at behandle sekundær hyperparatyroidisme hos patienter med alvorlig nyresygdom, der kræver dialyse for at rense blodet for affaldsstoffer.
treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products.
at behandle sekundær hyperparatyroidisme hos patienter med alvorlig nyresygdom, som har behov for dialyse for at fjerne affaldsprodukter fra blodet.
to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products
at behandle sekundær hyperparatyroidisme hos patienter med alvorlig nyresygdom, som har behov for dialyse for at fjerne affaldsprodukter fra blodet.
to treat secondary hyperparathyroidism in patients with serious kidney disease who need dialysis to clear their blood of waste products.
at behandle visse typer af hjerteanfald og alvorlige tilfælde af angina (smerte, som skyldes forsnævring i blodkarrene omkring hjertet). at behandle blodpropper i blodkar nær hudoverfladen i benene (superficiel venetrombose).
treat some types of heart attack and severe angina (pain caused by narrowing of the arteries in the heart). treat blood clots in blood vessels that are near the surface of the skin of the legs (superficial- vein thrombosis).
at behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals
at behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret, at den sygdom, som lægemidlet er beregnet til at fremkalde immunitet mod, stort set ikke forekommer i det pågældende område.
the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals. the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.
at behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter, der hidrører fra behandlede dyr, ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
At behandling af dyr med lægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter, hidrørende fra behandlede dyr, ikke er kontamineret.
the administration of the veterinary medicinal product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med veterinærlægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med veterinærlægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of a national programmes for the diagnosis, control and/or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med veterinærlægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med veterinærlægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
At behandling af dyr med veterinærlægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
The administration of the veterinary medicinal product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med veterinærlægemidlet griber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
At behandling af dyr med veterinærlægemidletgriber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
The administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
at behandling af dyr med veterinærlægemidletgriber forstyrrende ind i gennemførelsen af et nationalt program til diagnosticering, bekæmpelse eller udryddelse af sygdomme hos dyr eller gør det vanskeligt at bekræfte, at levende dyr eller levnedsmidler eller andre produkter hidrørende fra behandlede dyr ikke er kontamineret,
the administration of the product to animals will interfere with the implementation of national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
At behandling for hypersensitivitetsreaktioner, herunder forholdsregler for genoplivning, skal være tilgængelig under administration
That treatment for hypersensitivity reactions, including measures for resuscitation should be available during administration
At behandling med Nivolumab BMS kan øge risikoen for:
That Nivolumab BMS treatment may increase the risk of:
At behandling med OPDIVO kan øge risikoen for:
That OPDIVO treatment may increase the risk of:
At behandling med STAYVEER er forbundet med et fald i hæmoglobin.
That treatment with STAYVEER is associated with a decrease in haemoglobin.
At behandling med STAYVEER kan være forbundet med nedsat spermatozotal.
That treatment with STAYVEER might be associated with a decrease of sperm count.
At behandling med Thelin ofte forårsager et fald i hæmoglobin og tilknyttede røde blodlegemers parametre
That treatment with Thelin often causes a decrease in haemoglobin and related red cell parameters
At behandling med Tracleer er forbundet med et fald i hæmoglobin. o Behov for monitorering af blodet
That treatment with Tracleer is associated with a decrease in haemoglobin. o Need for blood monitoring
At behandling med Tracleer kan være forbundet med nedsat spermatozotal.
That treatment with Tracleer might be associated with a decrease of sperm count.
At behandling med Volibris medfører perifere ødemer og væskeretention
That treatment with Volibris causes peripheral oedema and fluid retention
At behandling med Volibris ofte medfører et fald i hæmoglobin og hæmatokrit
That treatment with Volibris often causes a decrease in haemoglobin and haematocrit
At behandlingen med LEMTRADA kan øge risikoen for:
That LEMTRADA treatment may increase the risk of:
at blive ældre
getting older
At blodsukkeret skal overvåges nøje under skiftet og de første uger herefter;
That blood glucose need to be closely monitored during the switch and the initial weeks thereafter;
At Bronchitol ikke er undersøgt hos patienter med signifikante episoder af hæmoptyse (>60 ml) i de foregående tre måneder.
That Bronchitol has not been studied in patients with a history of significant haemoptysis (>60 ml) in the previous three months.
At brugen af Atripla bør undgås med samtidig eller nylig brug af nefrotoksiske lægemidler.
That use of Atripla should be avoided with concomitant or recent use of nephrotoxic medicinal products.
At brugen af Stribild bør undgås med samtidig eller nylig brug af nefrotoksiske lægemidler.
That use of Stribild should be avoided with concomitant or recent use of nephrotoxic medicinal products.